Study on Sacituzumab Tirumotecan (Sac-TMT, MK-2870) for Treating Breast Cancer

Inclusion Criteria

• Have early-stage, high-risk breast cancer that has not spread to other parts of the body.
• The cancer must be either triple-negative or hormone receptor-low positive/HER2 negative.
• Must provide a biopsy sample from the breast tumor for testing.
• Be in good overall health with an ECOG performance status of 0 or 1.
• Have adequate organ function as determined by medical tests.

Exclusion Criteria

• Have breast cancer that has spread to other parts of the body (Stage IV) or involves certain lymph nodes.
• Have received any previous treatment for the current breast cancer diagnosis, including surgery or radiation.
• Have had certain types of biopsies or lymph node surgeries before starting the study treatment.
• Have received any cancer treatment or investigational drugs within four weeks before joining the study.
• Have previously been treated with specific immune therapies or drugs targeting TROP2 or topoisomerase I.
• Have received a live vaccine within 30 days before starting the study treatment.
• Have another active cancer that has required treatment in the past five years.
• Have uncontrolled systemic diseases or a history of lung conditions requiring steroids.